The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.25
Bid: 4.00
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 0.50 (12.50%)
Open: 4.25
High: 4.25
Low: 4.25
Prev. Close: 4.25
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ecovelexâ„¢2023 Approval in Italy

18 Dec 2023 07:00

RNS Number : 0576X
Eden Research plc
18 December 2023
 

As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

Eden Research and Corteva Agriscience Announce Ecovelex?2023 Approval in Italy

 

The innovative seed treatment helps farmers safely repel birds 

 

 

Cremona, Italy and Abingdon, UK - December 18, 2023 - Corteva Agriscience and Eden Research are pleased to announce that Ecovelex? 2023 has been granted, according to Reg. EU/1107/2009, a temporary approval in Italy for use as a bird repellent seed treatment in corn for the 2024 growing season. Eden is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products.

 

Developed by Corteva and Eden, Ecovelex represents a new entrant into the seed treatment market and is an alternative to conventional chemicals that are not approved in the EU and UK. It was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. 

 

Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources.

 

The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system. It is designed to support farmers as they strive to meet consumer and regulatory demands for more sustainable agriculture.

 

Leonardo Costa, EMEA Seed Applied Technologies Leader at Corteva Agriscience, said, "We are pleased to announce that farmers in Italy will have the opportunity to use maize seed that has been treated with Ecovelex to help control the damage frequently caused by birds. Ecovelex is a safe, effective and sustainable alternative to conventional crop protection products. Every year, farmers face heavy losses caused by birds, and recent regulatory changes have meant that the conventional approaches to combating crop damage are no longer available. 

 

"This represents a huge step forward in sustainable plant chemistry. Eden's team has done an excellent job of helping us tackle one of the tremendous challenges faced by today's farmers, and we look forward to expanding upon this work in the future."

 

Sean Smith, Eden CEO, said, "Eden's collaboration with Corteva Agriscience over the past several years has been highly productive, and I am pleased to see the first real-world benefits from these activities supporting farmers' requirements in Italy.

 

"Together, we are bringing another safe and effective product to market in near record time through efficient, open collaboration. This is ultimately a win for farmers who will have a new, effective tool for improving crop yields, safely and sustainably."

 

Eden has submitted the regulatory dossier and application to Austria, which will act as the interzonal rapporteur member state on behalf of the EU. Review and authorisation can take between 18 and 24 months, with each EU member state then able to ratify the authorisation or require additional information before granting local authorisations.

 

 

Notes to Editors:

 

About Eden

 

Eden is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information, please visit: www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

 

About Corteva 

 

 Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfils its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

 

Follow Corteva on FacebookInstagramLinkedInTwitter and YouTube. 

 

Contacts

 

Eden Research plc

Sean Smith Alex Abrey

www.edenresearch.com

+44 (0) 1285 359 555

 

 

Cavendish Capital Markets Limited (Nominated advisor and broker)

Giles Balleny / George Lawson (corporate finance)Michael Johnson (sales)

 

+44 (0) 20 7220 0500

Hawthorn Advisors (Financial PR to Eden Research plc)

Simon Woods

Victoria Ainsworth

eden@hawthornadvisors.com

 

Corteva Media Enquiries

József Máté, Corporate Communications Leader, EMEA

 

jozsef.mate@corteva.com +41 22 775 36 70

+41 79 597 2709

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGPGUPPUPWGRA
Date   Source Headline
31st Jan 20247:00 amRNSBoard Change
22nd Jan 20247:00 amRNSTrading Update
19th Jan 20243:00 pmRNSHolding(s) in Company
9th Jan 20247:01 amRNSMevalone Approval in the State of California
18th Dec 20237:00 amRNSEcovelexâ„¢2023 Approval in Italy
28th Nov 20237:00 amRNSSmall Cap Virtual Investor Conference
1st Nov 20237:00 amRNSChange of Nominated Adviser and Broker
9th Oct 20234:44 pmRNSHolding(s) in Company
9th Oct 20234:39 pmRNSHolding(s) in Company
9th Oct 202312:46 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSCompletion of Conditional Placing
29th Sep 20237:01 amRNSHalf Yearly Report
29th Sep 20237:00 amRNSCapital Raising Update
31st Aug 20236:25 pmRNSGrant of Awards under Long-Term Incentive Plan
17th Aug 20239:27 amRNSResult of GM and Capital Raising update
16th Aug 20237:00 amRNSFirst Order For Ecovelex
2nd Aug 20233:22 pmRNSResult of Retail Offer
28th Jul 20235:00 pmRNSRetail Offer
28th Jul 20235:00 pmRNSPlacing and Retail Offer
3rd Jul 20237:00 amRNSRegulatory Application for Ecovelex in the UK
30th Jun 20239:17 amRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSAppointment of New Product Distributor – Colombia
9th Jun 20234:29 pmRNSHolding(s) in Company
7th Jun 20237:00 amRNSPublication of Annual Report and Notice of AGM
5th Jun 20234:47 pmRNSHolding(s) in Company
30th May 20237:00 amRNSEden and Corteva seek to bring Ecovelex to market
17th May 20237:00 amRNSExercise of Options
15th May 20237:00 amRNSMevalone authorisation in New Zealand
12th May 20237:00 amRNSRegulatory approvals in California and Florida
5th May 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
17th Apr 20237:00 amRNSRegulatory authorisation for Mevalone in Poland
23rd Mar 20237:00 amRNSUS State Regulatory Approvals Update
30th Jan 20237:00 amRNSFirst Mevalone authorisation for domestic use
10th Jan 20237:00 amRNSTrading Update
15th Dec 20222:01 pmEQSEden Research signs new Mevalone distribution deal
15th Dec 20227:00 amRNSDistribution Agreement for Mevalone in France
30th Nov 20227:00 amRNSOrganic Certification in Greece
24th Oct 202212:00 pmRNSAIM Rule 17 Notification
3rd Oct 20224:39 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSEden Half Yearly Report
28th Sep 20228:46 amRNSAppointment of Auditor
27th Sep 20225:08 pmEQSEden granted US EPA regulatory approval
26th Sep 20227:00 amRNSEden granted US EPA regulatory approval
2nd Sep 20227:00 amRNSAppointment of Non-Executive Director
22nd Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSExercise of Options
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.